Current Treatment Options in Cardiovascular Medicine

, 16:326

The Role of Novel Anticoagulants in the Management of Venous Thromboembolic Disease

Authors

  • Dalene Bott Kitslaar
    • Division of Cardiovascular MedicineMayo Clinic and Foundation
  • Waldemar E. Wysokinski
    • Division of Cardiovascular MedicineMayo Clinic and Foundation
    • Division of Hematology ResearchMayo Clinic and Foundation
    • Division of Cardiovascular MedicineMayo Clinic and Foundation
    • Division of Hematology ResearchMayo Clinic and Foundation
Vascular Disease (R Schainfeld, Section Editor)

DOI: 10.1007/s11936-014-0326-1

Cite this article as:
Kitslaar, D.B., Wysokinski, W.E. & McBane, R.D. Curr Treat Options Cardio Med (2014) 16: 326. doi:10.1007/s11936-014-0326-1
Part of the following topical collections:
  1. Topical Collection on Vascular Disease

Opinion statement

The introduction of oral direct coagulation factor inhibitors is dramatically changing the landscape of anticoagulation delivery in patients experiencing or at risk for a thrombotic event. These novel anticoagulants can be particularly attractive for health care providers, as they deliver therapeutic anticoagulation at a fixed dose, require no routine coagulation monitoring, and have few drug interactions and no food restrictions. Herein, we will review the role of these novel anticoagulants for acute venous thromboembolism treatment, primary and secondary venous thromboembolism prevention, and management during the periprocedural period.

Keywords

Novel anticoagulantsRivaroxabanDabigatranApixabanEdoxabanVenous thromboembolism treatment (VTE)

Copyright information

© Springer Science+Business Media New York 2014